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To evaluate the role of amoeba-associated bacteria as
agents of ventilator-associated pneumonia (VAP), we test-
ed the water from an intensive care unit (ICU) every week
for 6 months for such bacteria isolates; serum samples and
bronchoalveolar lavage samples (BAL) were also obtained
from 30 ICU patients. BAL samples were examined for
amoeba-associated bacteria DNA by suicide-polymerase
chain reaction, and serum samples were tested against
ICU amoeba-associated bacteria. A total of 310 amoeba-
associated bacteria from 10 species were isolated. Twelve
of 30 serum samples seroconverted to one amoeba-asso-
ciated bacterium isolated in the ICU, mainly Legionella
anisa and Bosea massiliensis, the most common isolates
from water (p=0.021). Amoeba-associated bacteria DNA
was detected in BAL samples from two patients whose
samples later seroconverted. Seroconversion was signifi-
cantly associated with VAP and systemic inflammatory
response syndrome, especially in patients for whom no eti-
ologic agent was found by usual microbiologic investiga-
tions. Amoeba-associated bacteria might be a cause of
VAP in ICUs, especially when microbiologic investigations
are negative. 
H
ospital-acquired pneumonia occurs in 0.5% to 1% of
admitted patients admitted, representing 10% to 15%
of all nosocomial infections; pneumonia is the most com-
mon cause of nosocomial infection in intensive-care units
(ICUs) (1). This pneumonia is associated with high death
rates. As the etiologic agent of pneumonia remains
unknown in 20% to 50% of cases (2), identifying new lung
pathogens is a major public health goal. Aquatic bacteria
such as Legionella  spp., Pseudomonas  spp., Stenotro-
phomonas spp., Burkholderia spp., or Acinetobacter spp.
may colonize in hospital water supplies and have previous-
ly been shown to be causally associated with cases of noso-
comial infections (3). Free-living amoebae have been
shown to be a reservoir of pathogens such as Legionella sp.,
Burkholderia picketti, and Cryptococcus neoformans (4–7).
The most studied amoebae-associated bacterium is
Legionella pneumophila, the agent of Legionnaires’disease
(8), which frequently results from exposure to contaminat-
ed aerosols. Additional amoeba-associated bacteria might
be implicated in community-acquired pneumonia, includ-
ing Legionella-like amoebal pathogens (9) and members of
the genus Parachlamydia (10). As part of research into the
diversity of bacterial agents associated with amoebae in
hospital water supplies, we have identified a new α-
Proteobacteria belonging to the Bradyrhizobiaceae family
(11–13). We demonstrated that patients with nosocomial
pneumonia hospitalized in the vicinity of the contaminated
water in a public hospital of our city have elevated antibody
titers to these bacteria (14). In this study, we performed the
same kind of analysis but focused our work on a single ICU
during a 6-month period. Amoeba-associated bacteria were
periodically evaluated in all ICU water taps. To evaluate
contact of patients hospitalized in this ICU and amoeba-
associated bacteria in the water, serum and bronchoalveolar
lavages (BAL) samples were periodically sampled. Serum
samples were tested in an immunofluorescence assay
against the isolated bacteria to detect seroconversions, and
DNA of these bacteria were detected in BAL samples by
suicide-polymerase chain reaction (PCR) (15,16), a PCR
technique without positive controls that incorporates “dis-
posable” primers to avoid false-positive results. The second
part of this work was to evaluate if exposure to the amoe-
ba-associated bacteria in the ICU could be associated with
disease. Thus, we specifically studied some clinical mark-
ers of infection, including fever, systemic inflammatory
response syndrome (SIRS), and pneumonia for patients
admitted to the ICU. As a definition of pneumonia based
only on clinical and roentgenographic criteria has been crit-
icized for low specificity (17–19), we used strict criteria in
the definition. These criteria were applied to cases in which
bacterial documentation was negative to determine if dis-
ease observed in patients hospitalized in an ICU may be
attributed to amoeba-associated bacteria.
Materials and Methods
All patients admitted to the ICU during a 26-week
period who needed intubation and mechanical ventilation
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Acute Physiology and Chronic Health Evaluation II score
(20). At admission and every week thereafter, temperature,
leukocytes and platelet counts, hepatic enzymes, and pres-
ence of SIRS and ventilator-associated pneumonia (VAP)
were recorded. Serum samples were obtained from
patients at admission, every 7 days afterwards, and at dis-
charge. BAL was obtained at admission immediately after
intubation by using protected mini-bronchoalveolar lavage
(Combicath, Plastimed, Le-Plessy-Bouchard, France),
then performed when a lung infiltrate suggestive of pneu-
monia appeared, and repeated every week until pneumonia
resolved. BALs are part of the routine diagnosis and fol-
low-up of pneumonia in the ICU and were not performed
specifically for the study. Informed consent was obtained
from the patient’s family, according to French legislation.
Data about bacteria isolated from blood cultures, lung
secretions, and urine by conventional procedures were
recorded. When isolated from urine and lung secretions,
bacteria were only considered as pathogenic when concen-
tration in the specimen was >105 and >106 CFU/mL,
respectively (21).
Definitions of VAP and SIRS were based on previously
published criteria (22–25), but to increase specificity, we
limited our study to severe cases of VAP by adding strict
criteria (Table 1). Taps and ice machine water were sam-
pled every other week, as previously reported (11). The
procedure for isolating bacteria from water and lung secre-
tions by using cocultivation with Acanthamoeba polypha-
ga followed by subculture onto BCYE agar plates has been
detailed elsewhere (11,26). Bacteria were identified by
using 16S rRNA gene sequence comparisons as previous-
ly described (27). Legionella species were identified by
using mip gene amplification and sequencing (28).
Twenty bacterial antigens were tested by microim-
munofluorescence as previously reported (14,29).
Bacterial species isolated from the ICU water during the
studied period and 10 other species previously isolated in
the same conditions from other sites (Bosea eneae, B.
vestrisii, B. thiooxydans, Mesorhizobium amorphae,
Azorhizobium caulinodans, Afipia felis, A. felis
genospecies A, A. clevelandensis, A. birgiae, and A. mas-
siliae [11–14]) were tested. The serologic tests were per-
formed on the first serum samples from all patients admit-
ted to the ICU; these patients were available for a second
sample (30 patients). The control group comprised 10
patients in the same ICU. These patients had shorter stays
and had samples taken at admission but was not available
(100 patients) and 114 patients with other diseases, includ-
ing Q fever (10 samples), trench fever (5 samples),
tularemia (8 samples), Mediterranean spotted fever (10
samples), epidemic typhus (5 samples), syphilis (10 sam-
ples), cat scratch disease (5 samples), pneumonia caused
by Chlamydia pneumoniae (5 samples), C. psittaci (5 sam-
ples),  Mycoplasma pneumoniae (10 samples), L. pneu-
mophila (10 samples), hepatitis C virus (5 samples), infec-
tions caused by cytomegalovirus (5 samples), Epstein Barr
virus (11 samples), and HIV (10 samples). Serum samples
were diluted at 1:25, 1:50, and 1:100 for immunoglobulin
(Ig) G and IgM determination. The cutoff titer for a posi-
tive detection was determined as the lowest titer for which
all first serum samples and control serum samples were
negative. Then, all patients’serum samples were tested and
serial twofold dilutions from 1:50 to 1:1600 were made on
these samples with titers at least equal to the cutoff titer.
Tests by Western blot were performed as previously
described (29) for any patient with a seroconversion. 
DNA was extracted from BAL samples by using
QIAMP Tissue kit (QIAGEN, Hilden, Germany), accord-
ing to the manufacturer’s instructions. PCR detection was
attempted on all BAL samples for bacteria against which at
least one seroconversion was generated. DNA extraction
from serum samples was performed in a laboratory other
than the one in which the isolates were identified to avoid
vertical contamination from previous amplifications, and
no positive control was used to avoid horizontal contamina-
tion from the same experiment (16). We used a nested PCR
that incorporated two primer pairs used only once (Table 2)
followed by sequencing and comparison to the targeted
sequence, as previously described for suicide-PCR (15,16).
All samples were tested the same day in the same assay.
Sample testing was blinded, and positive amplicons were
sequenced. Negative controls consisted of BAL samples
from 10 patients of the same ICU obtained at admission,
BAL samples from 200 patients with nosocomial pneumo-
nia hospitalized in other medical centers of the city, water
samples, and a suspension of A. polyphaga. At least one
negative control was used for every two serum samples.
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Table 1. Definition criteria for ventilator-associated pneumonia (VAP) and systemic inflammatory response syndrome (SIRS) 
VAP  SIRS  Unexplained VAP  Unexplained SIRS 
New and persistent roentgenographic lung 
infiltrate and new onset of: 
a) Increase in white blood cells >10 g/L 
b) Fever or hypothermia (>38°C or <36°C)  
c) Purulent sputum 
d) Duration of at least 2 weeks 
e) PaO2/FiO2 ratio <100 
At least two of: 
a) T° >38°C or <36°C 
b) Heart rate >90/min 
c) Respiratory rate >20/min or PaCO2  
<32 mmHg 
d) Leukocytes >12 or <4 g/L or immature 
(band) forms 
Lack of recovery of 
bacteria from:  
a) Lung secretions  
b) Blood cultures 
Lack of recovery of bacteria from: 
a) Lung secretions  
b) Blood cultures 
c) Urine Comparisons of demographic, clinical, and laboratory
data between patients with evidence of amoeba-associated
bacteria contact (seroconversion or positive detection in
BAL samples) were performed by using chi square and
Mann-Whitney tests, respectively. The tested variables
were age; sex; an underlying disease; severity score; intu-
bation duration; hospitalization duration; SIRS; death;
increase of hepatic enzymes, platelet count, and leuko-
cytes; VAP; and fever. We also compared demographic,
clinical, and laboratory data between patients with and
without unexplained VAP, fever, and SIRS. Multivariate
analysis adjusted for age, sex, prolonged intubation, and an
underlying disease was performed to confirm observed
associations. STATA software (v. 7.0, Stata Corporation,
College Station, TX) was used for analysis.
Results
Ten species (310 isolates) were identified from 864
water samples (Table 3). B. massiliensis and L. anisa were
the two most commonly isolated species (62.3% of the 310
isolates). In the ICU admission rooms , isolation of L.
anisa ranged from 75% to 100% of the tested taps during
the first 20 weeks; whereas all were negative during the
last 6 weeks, after taps were changed. No amoeba-associ-
ated bacteria were isolated from BAL.
Ninety serum samples from the 30 patients and the 214
control serum samples were tested by an immunofluores-
cence assay for IgG and IgM on the 20 amoeba-associated
bacteria antigens (12,160 tests). The 30 first serum sam-
ples and the samples from blood donors did not have an
IgG titer of >1:50 or IgM titer >1:25. Cutoff titers for pos-
itive serologic tests with 100% specificity are shown in
Table 4. Twelve (40%) patients seroconverted from 10 to
35 days after admission to at least one antigen; 10 showed
IgM antibodies (Table 5). Five patients seroconverted to L.
anisa, six to B. massiliensis, including one to both, one to
L. quinlivanii, and one to A. broomeae. Western blots con-
firmed the seroconversions, with the appearance of sever-
al reacting bands on convalescent-phase serum samples
(Figure). Patients also seroconverted to amoeba-associated
bacteria not detected in the water in this study: two to
A. clevelandensis (patient 2, IgG=1:100 and IgM=1:100;
patient 8, IgG=1:50 and IgM=1:200;) and two to A. felis
(patient 2, IgG=1:100 and IgM=1:100; patient 9,
IgG=1:1600 and IgM=1:25). Seroconversions were signif-
icantly more frequent against amoeba-associated bacteria
obtained in this ICU than against amoeba-associated bac-
teria isolated in previous studies: 13 of 300 tests versus 4
of 300 tests and 12 of 30 patients versus 4 of 30 patients
(p=0.046 and p=0.039, respectively). Patients also sero-
converted more frequently to the most commonly isolated
bacteria,  L. anisa and  B. massiliensis (>50 isolates,
p=0.021). 
Table 6 shows the clinical characteristics of patients
with serologic evidence of exposure to amoeba-associated
bacteria isolated in the ICU. Analysis for risk and potential
confounding factors did not indicate differences between
patients with or without seroconversion. However, sero-
conversion was statistically associated with VAP
(p=0.026), unexplained VAP (p=0.034), SIRS (p=0.024),
and unexplained SIRS (p=0.045). Multivariable logistic
regression demonstrated that seroconversion was inde-
pendently associated with VAP even after we adjusted for
intubation duration, hospitalization duration, number of
serum samples, and underlying disease (p=0.014 to 0.030).
The DNA of L. anisa and B. massiliensis were each
detected once in the 66 BALsamples from 30 patients. For
two samples, seroconversion to the identified bacteria, L.
anisa and B. massiliensis, respectively, was observed 4
and 2 weeks after the PCR was positive in BAL. None of
the 210 control patients was positive for these bacteria in
BAL samples compared to 2 of 30 patients in the ICU
(p<0.01).
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Table 2. Polymerase chain reaction primers used for amplification and sequencing of bacterial DNA within human samples 
Primers  Bosea-related strain  Legionella anisa  Afipia broomeae  L. quinlivanii 
External forward  5′-TGCGAGTGTA 
GAGGTGAAATT-3′ 
5′-TATTGGTGC 
TGATTTAGGAA-3′ 
5′-TCTTTTGTGCG 
GGAAGATAATG-3′ 
5′-TTGTTGATGTTT 
GTTTTGAGACC-3′ 
External reverse  5′CGCTCGTTG 
CGGGACTTAA-3′ 
5′-GCTAAGTCTGAA 
GGTACA-3′ 
5′-TAAACTTTCCAA 
CGGCTGGCAT-3′ 
5′-TTCAACACTTCT 
TTCATCTGATC-3′ 
Internal forward  5′-GAGGTGAAA 
TTCGTAGATATT-3′ 
5′-GCCCAATTG 
ATTTTGACAG-3′ 
5′-GCTAACTTCGT 
GCCAGCAG-3′ 
5′-TCCAAGAATAA 
AAGGGGATTG-3′ 
Internal reverse  5′-GAGCTGACG 
ACAGCCAT-3′ 
5′-GCATTAATTGT 
AATGCTTCA-3′ 
5′-GTTTGCTCC 
CCACGCTTTC-3′ 
5′-CCATACCAT 
CCTGTAAGCCTT-3′ 
Table 3. Identification of the 310 bacterial strains isolated by 
using amoebal co-culture procedure 
Species  No. of isolates 
Legionella anisa  126 
Bosea massiliensis  67 
Rasbo bacterium  45 
Bradyrhizobium liaoningense  29 
L. quinlivanii  12 
L. pneumophila  11 
L. rubrilucens  7 
L. worsleiensis  6 
B. japonicum  5 
Afipia broomeae  2 The death rate was 33.3%; disease was mainly associ-
ated with fever (96.6%), VAP (56.6%), and SIRS (76.6%).
No microbial etiologic agent was found in 18 (62%) of 29
patients with fever, 10 (43%) of 23 patients with SIRS, and
in 8 (47%) of 17 patients with VAP. VAP was significantly
associated with duration of hospitalization  (median hospi-
talization days/interquartile range of 23/18–41 with VAP
versus 14/10–21 without VAP, p=0.04), SIRS (16/17 with
VAP versus 7/13 without VAP, p=0.025) and seroconver-
sion to amoeba-associated bacteria (10/17 with VAPversus
2/13 without VAP, p=0.026). No other statistical difference
was observed between patients with VAPand without VAP
in terms of demographic, clinical, and paraclinical data,
risks, and potential confounding factors. Most patients
received cephalothin for the first 3 days of hospitalization
as an antibiotic prophylaxis. The most commonly used
antibiotics in patients with VAP were third-generation
cephalosporins. Patients with VAP received antibiotics
more frequently and for more than 1 week (16/17 with
VAP versus 7/13 without VAP, p=0.025).
Discussion
We confirmed that several amoeba-associated bacteria
are common in the water in ICU; we recovered 310 amoe-
ba-associated bacteria isolates from 10 species from the
water of the ICU. As exposure to a microorganism is a pre-
requisite to infectious disease, we first evaluated contact of
patients hospitalized in the ICU with amoeba-associated
bacteria in water. We found that 12 (40%) of 30 of patients
seroconverted to amoeba-associated bacteria and that these
seroconversions were significantly more common against
local isolates than to amoeba-associated bacteria from
other ICUs. Moreover, antibody response parallels that of
water contamination with B. massiliensis and L. anisa,
which cause 83% of seroconversions identified in 62% of
isolates (p=0.021). The cutoff titers, chosen to have 100%
specificity, and the detection of several reactive antigens in
the Western blots (Figure) suggest that these seroconver-
sions represent specific serologic reactions. Detection of
antibodies reacting to amoeba antigens would also be
important because infections could occur through inhala-
tion (perhaps after colonization) of infected amoebae act-
ing as a “Trojan horse” (6). In future studies, isolation of
amoebae in the aquatic environment as in the BAL sam-
ples of patients will be performed for further use as anti-
gens.
Patient exposure to amoeba-associated bacteria from
the ICU was also evident in results of amoeba-associated
bacteria DNA detection in BAL samples from 2 of 30
patients as compared with 0 of 210 control patients
(p<0.01). Moreover, for these patients, bacterial DNA was
detected in the BAL sample before the seroconversion to
the same bacteria 2 to 4 weeks after admission. This rate is
compatible with an acute infection occurring during hospi-
talization rather than colonization of the respiratory tracts
of patients. Contamination is unlikely when using a sui-
cide-PCR procedure (15,16). Isolation of these agents was
probably hampered by the antibiotic prophylaxis instituted
at admission in this ICU for trauma patients and likely
explains the lack of amoeba-associated bacteria isolation
in BAL samples.
Among the 30 patients, VAP occurred frequently
(56.6%) and was associated with hospitalization duration,
as previously reported (30,31). Of the patients with VAP,
58.8% seroconverted to amoeba-associated bacteria, as
compared to 15.4% of the remaining 13 patients
(p=0.026). In patients with seroconversion, SIRS was also
more prevalent (p=0.024). The percentages of unexplained
VAPand unexplained SIRS were four times more common
in amoeba-associated bacteria seroconverters than in non-
seroconverters and remained statistically significant in
spite of the small population studied (Table 6). Thus,
amoeba-associated bacteria may be a common cause of
unexplained VAP and SIRS.
Finally, we identified a cryptic outbreak in the ICU
caused by L. anisa, a pathogen commonly encountered in
the environment (32,33), only implicated in a few epi-
demics of Pontiac fever (34,35) and four cases of legionel-
losis (26,36–38). Five (16.7%) of 30 patients were infect-
ed with this bacterium, considered a relatively rare
pathogen. Serologic tests are not currently used for L.
anisa, and no urinary antigen test is available. Therefore,
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Table 4. Definition of cutoff titers for positive serologic tests and 
100% specificity according to antigen tested by using the 224 
control serum samples
a 
Antigen  IgG  IgM 
Legionella anisa  >1:50  >1:25 
Bosea massiliensis  >1:50  >1:25 
Rasbo bacterium  >1:100  >1:25 
Bradyrhizobium liaoningense  >1:50  >1:25 
L. quinlivanii  >1:100  >1:25 
L. pneumophila  >1:50  >1:25 
L. rubrilucens  >1:200  >1:25 
L. worsleiensis  >1:200  >1:25 
B. japonicum  >1:100  >1:25 
Afipia broomeae  >1:200  >1:25 
Bosea eneae  >1:800  >1:25 
B. vestrisii  >1:100  >1:25 
B. thiooxydans  >1:50  >1:25 
Mesorhizobium amorphae  >1:100  >1:25 
Azorhizobium caulinodans  >1:100  >1:25 
Afipia felis  >1:100  >1:25 
A. felis genospecies A  >1:100  >1:25 
A. clevelandensis  >1:100  >1:25 
A. birgiae  >1:50  >1:25 
A. massiliae  >1:50  >1:25 
aIg, immunoglobulin. diagnosis based only on isolation may explain why L.
anisa is so rarely reported. However, its absence in the
BAL samples from the 200 patients from other ICUs
shows that local epidemiology plays a major role. This
study confirms that L. anisa is common in the environment
(32,33).
Members of the Bosea genus are gram-negative, oxi-
dase-positive, catalase-positive rods belonging to the α-2
subgroup of Proteobacteria. All are motile. They grow well
on BCYE agar from 25°C to 37°C but do not grow or grow
weakly on Columbia agar with 5% sheep blood. Colonies
are smooth, mucoid, round, and cream colored and are ure-
ase positive and α-hemolytic on Columbia agar with 5%
sheep blood and 0.2% yeast extract. B. massilensis are
negative in assays for arginine dihydrolase activity, esculin
and gelatin hydrolysis, β-galactosidase activity, maltose
assimilation, and acid production by fermentation or oxi-
dation of substrates tested in API 50 CH (Biomérieux,
Marcy l’étoile, France), especially D-glucose, D-fructose,
D-mannose, and sucrose. The species of the Bosea genus
have high MICs to penicillin and amoxicillin and low
MICs to doxycycline (13). In co-culture with A. polypha-
ga, B. vestrisii, B. eneae, and B. massiliensis are phagocyt-
ed and form progressively large vacuoles that lead to
amoebal lysis; however, they have never been reported as
pathogenic agents before. As B. massiliensis has not been
tentatively isolated elsewhere, whether our findings reflect
a local phenomenon or whether the bacterium is widely
encountered is not known. We think that our data support
the role of B. massiliensis in severe VAP, but confirmation
is needed to definitely establish a role.
Our study indicates that most patients with VAP
received  β-lactam agents, mainly amoxicillin-clavulanic
acid and third-generation cephalosporin. These antibiotics
may have inhibited bacterial culture, which explains why
no amoeba-associated bacteria were isolated from BAL
samples. B. massiliensis has low MICs (<0.5 mg/L) to cef-
triaxone, doxycycline, rifampin, and erythromycin (13).
However,  β-lactam agents are also active in vitro on
Legionella  spp., but animal models and clinical studies
have demonstrated their inefficacy in the treatment of
legionellosis (39).
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Table 5. Antibody titers of 12 serum samples with seroconversion to at least one of the bacteria isolated in the intensive care unit  
Bosea massiliensis  Legionella anisa  L. quinlivanii  Afipia broomeae 
Case  Wk of sampling  IgG  IgM  IgG  IgM  IgG  IgM  IgG  IgM 
1      <1:50  <1:25         
4      1:50  1:100         
1
a 
7      1:800  1:50         
2
 a  1  <1:50  <1:25             
  3  1:400  1:100             
7  1      <1:50  <1:25         
  3      <1:50  1:200         
8  1          <1:50  <1:25     
  3          1:200  1:800     
9  1  <1:50  <1:25  <1:50  <1:25         
  3  1:400  1:50  1:50  1:400         
  5  1:50  1:25  1:800  1:50         
11  1  <1:50  <1:25             
  5  1:50  1:50             
12  1      <1:50  <1:25         
  3      1:400  1:50         
13  1              <1:50  <1:25 
  3              1:50  <1:25 
  5              1:100  <1:25 
  7              1:200  <1:25 
19  1      <1:50  <1:25         
  3      1:400  <1:25         
22  1  <1:50  <1:25             
  3  1:200  1:50             
23  1  <1:50  <1:25             
  5  1:400  1:25             
28  1  <1:50  <1:25             
  3  1:400  1:25             
  5  1:200  1:25             
aPatients with positive PCR results in bronchoalveolar lavage samples (patient 1, L. anisa; Patient 2, B. massiliensis); Ig, immunoglobulin. All patients were sampled at 
admission (wk 1); titers in bold are those greater than or equal to defined cutoff titers (Table 4). The results of our study confirm that the bacteriologic
tests of hospital water supplies is largely ignored. Our work
demonstrates that patients are exposed specifically to the
most common water amoeba–associated bacteria in their
environment, as evidenced by seroconversion against these
bacteria and DNA of these bacteria in BAL samples. The
route of infection, even if caused by aerosols generated in
the ICU, remains unclear. Patients of this ICU sometime
receive water through nasogastric tubes but only bottled,
sterile water. However, we cannot exclude mistakes caused
by not following recommended procedures. Patients for
whom exposure to these bacteria is supported by serocon-
version or DNA detection in BAL samples have unex-
plained VAP and SIRS more commonly. We speculate that
amoeba-associated bacteria in the environment of intubat-
ed patients may concurrently cause unexplained infections
and cryptic outbreaks. Research of new etiologic agents of
pneumonia in ICUs should be based on environmental
study of each ICU since ecologic findings of amoeba-asso-
ciated bacteria in water points in hospital vary.
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Figure. Western blot showing seroconversions in immunoglobulin
(Ig) G (Lanes 1, 3, 5, 7) and IgM (Lanes 2, 4, 6, 8) of patient 2
against Bosea massiliensis (Lanes 1 to 4) and patient 9 against
Legionella anisa (Lanes 5 to 8). Lanes 1, 2, 5, 6: acute-phase
sera; Lanes 3, 4, 7, 8: convalescent-phase sera. 
Table 6. Clinical characteristics of patients with or without seroconversion to one of the amoeba-associated bacteria
a 
Clinical characteristics  Seroconversion (N=12)  No seroconversion (N=18)  p value 
Demographic data       
Median age in y (IQR)  35 (25–43)  24 (21–52)  0.85 
Male (%)  10 (83.3)  15 (83.3)  1 
Risk and potential confounding factors       
Underlying disease (%)  2 (16.6)  3 (16.6)  1 
Circulation injury (%)  9 (75)  14 (77.8)  1 
Median APACHE II
a score (IQR)  21 (14–4)  23 (16–34)  0.12 
Intubation in ICU (%)  8 (66.6)  7 (38.9)  0.26 
Median hospitalization days (IQR)  25 (19–41)  17 (10–23)  0.094 
Median intubation duration in days (IQR)  11 (7–20)  11 (7–20)  0.8 
Median number of serum samples (IQR)  3 (3–5)  3 (2–4)  0.12 
Clinical data       
VAP (%)  10 (83.3)  7 (38.9)  0.026 
Unexplained VAP (%)  6 (50)  2 (11.1)  0.034 
Fever > 38.5 °C (%)  12 (100)  17 (84.4)  1 
Unexplained fever (%)  7 (58.3)  11 (39.3)  0.27 
SIRS (%)  12 (100)  11 (61.1)  0.024 
Unexplained SIRS (%)  7 (58.3)  3 (14.3)  0.045 
Death (%)  2 (16.7)  8 (44.4)  0.23 
Paraclinical data       
Leukocytes > 12 g/L (%)  12 (100)  14 (77.8)  0.13 
Platelets > 500 g/L (%)  5 (41.7)  6 (33.3)  0.7 
PCR detection of ARB in BAL samples(%)  2 (17)  0  0.15 
aIQR, interquartile range; VAP, ventilator-associated pneumonia; SIRS, Systemic Inflammatory Response Syndrome; APACHE II, Acute Physiology and Chronic Health 
Evaluation II; PCR, polymerase chain reaction; ARB, angiotensin receptor blockers; BAL, bronchoalveolar lavage samples; bold p values are those that are significant 
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